Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Feb 1;14(1):176-178.
doi: 10.21037/hbsn-24-613. Epub 2025 Jan 13.

Is immunotherapy-related liver injury more common in patients with hepatocellular carcinoma than in other advanced solid tumors?

Liang Wang  1 , Yonggang Wei  1 , Ming Zhang  1
Affiliations
Comment

Is immunotherapy-related liver injury more common in patients with hepatocellular carcinoma than in other advanced solid tumors?

Liang Wang et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Immunotherapy-related liver injury; advanced solid tumours; hepatocellular carcinoma (HCC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-613/coif). All authors report that this work was supported by the National Natural Science Foundation of China (grant No. 82270648). The authors have no other conflicts of interest to declare.

Comment on

  • Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    Celsa C, Cabibbo G, Fulgenzi CAM, Scheiner B, D'Alessio A, Manfredi GF, Nishida N, Ang C, Marron TU, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro FR, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato DJ. Celsa C, et al. J Hepatol. 2024 Mar;80(3):431-442. doi: 10.1016/j.jhep.2023.10.040. Epub 2023 Nov 15. J Hepatol. 2024. PMID: 37972660

References

    1. Celsa C, Cabibbo G, Fulgenzi CAM, et al. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol 2024;80:431-42. 10.1016/j.jhep.2023.10.040 - DOI - PubMed
    1. Peng X, Huang Y, Zhang M, et al. Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis. Dis Markers 2022;2022:3533714. 10.1155/2022/3533714 - DOI - PMC - PubMed
    1. Zhang LX, Lv Y, Xu AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer 2019;19:841. 10.1186/s12885-019-6011-8 - DOI - PMC - PubMed
    1. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68:1181-90. 10.1016/j.jhep.2018.01.033 - DOI - PubMed
    1. Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. 10.1038/s41586-021-03362-0 - DOI - PMC - PubMed

LinkOut - more resources